Medimaps Group, a med-tech company specializing in image processing software for the assessment of bone health, has secured USD 20 million in a financing round led by Swisscanto, alongside Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures. The funds raised will be used to expand its product portfolio with the development and market launch of its patented AI applications for bone health assessment in the U.S., Europe, Asia, and Latin America. The company’s current flagship product TBS iNsight has received medical reimbursement in the U.S. beginning January 1, 2022.

Written by

WITH US, YOU CANCO-INVEST IN DEEP TECH STARTUPS

Verve's investor network

With annual investments of EUR 60-70 mio, we belong to the top 10% most active startup investors in Europe. We therefore get you into competitive financing rounds alongside other world-class venture capital funds.

We empower you to build your individual portfolio.

Sign up to receive our regular newsletter and learn about investing in technologies that are changing the world.

Privacy Preference Center